All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Described herein are imaging devices and systems for use in biological probes. In particular, described herein are catheter-based imaging systems using Optical Coherence Tomography (OCT).
In intravascular surgery, as well as other medical applications, there is frequently a need to extend very thin (few millimeter diameter), long (30-150+cm), and sterile catheters into thin-walled (e.g., 1-1.5 millimeter wall thickness) biological lumens, including blood vessels such as arteries and veins.
A number of vascular diseases, such as coronary artery disease and peripheral vascular disease, are caused by the build-up of atherosclerotic deposits (plaque) in the arteries, which limit blood flow to the tissues that are supplied by that particular artery. Disorders caused by occluded body vessels, including coronary artery disease (CAD) and peripheral artery disease (PAD) may be debilitating and life-threatening. Chronic Total Occlusion (CTO) can result in limb gangrene, requiring amputation, and may lead to other complications and eventually death. Increasingly, treatment of such blockages may include interventional procedures in which a guidewire is inserted through a catheter into the diseased artery and threaded to the blocked region. There the blockage may be either expanded into a more open position, for example, by pressure from an inflated catheter balloon (e.g., balloon angioplasty), and/or the blocked region may be held open by a stent. Treatment of such blockages can also include using a catheter to surgically remove the plaque from the inside of the artery (e.g., an atherectomy).
There is medical interest in equipping catheters with sensors that can help direct the catheter for atherectomy, occlusion-crossing, and/or other surgical procedures. For example, it would be useful to have sensors that can give the surgeon immediate visual feedback as to whether a particular tissue is diseased and/or how far away the cutting portion of a catheter is from the boundary of a particular blood vessel layer to minimize the risk of accidental damage. Conventional radiological imaging methods and ultrasound imaging systems have been attempted for such surgical procedures. However, neither ultrasound nor radiological imaging methods have enough resolution to help guide the operation of the catheter through small dimensions. Moreover, standard radiological techniques cannot easily discriminate between healthy tissue and diseased tissue unless the tissue has become heavily calcified. Further, the components of an ultrasound system are generally too large to implement on a small scale, such as with a system configured to be used within blood vessels.
Optical Coherence Tomography (OCT) has been proposed as one technique that may be particularly helpful for imaging regions of tissue, including within a body lumen such as a blood vessel. At a basic level, OCT relies on the fact that light traveling from a source and scattering from more distant objects takes longer to travel back than light scattering from nearby objects. Due to the wave nature of light, very small timing differences caused by light signals traveling different distances on the micron scale can cause constructive or destructive interference with reference light signals. OCT systems measure the resulting interference to obtain an image of the target. A typical OCT system requires one or more interferometers to distinguish the signal from the applied light. In addition, most known OCT systems, when applied to catheters, include a fiber that is rotated (often at high rates) within the catheter in order to scan the lumen and a second, large reference arm.
Referring to
These traditional OCT systems, however, are large and cumbersome due to the required reference arm and are therefore generally ineffective for use in a medical catheter, particularly for use with a low cost and disposable catheter. Using a common path OCT system, i.e., a system without a separate reference arm, is one way to eliminate the cost and size of such an imaging catheter. There are several challenges, however, associated with developing a catheter having common path OCT. For example, a common path OCT system requires that the reference reflection be formed within the same optical conduit as the target reflection. This reference reflection must be finely tuned to avoid noise in the system, requiring that the path from the light source to the reflection interface be free of unnecessary components, such as focusing elements, that could interfere with the reference reflection. Further, the common path system must have components that are small enough to fit inside of a single small catheter, making it difficult to include additional components. Finally, for common path OCT, it is desirable to have the reference reflection as close to the tissue as possible to maintain the imaging range within the coherence length of the source and avoid data processing burden, as data processed for the distance between the reference and the start of the imaging is not useful. Accordingly, a common path OCT system that solves some of these problems is desired.
In general, in one embodiment, a system for optical coherence tomography includes a source of optical radiation, an optical fiber, and a graded index fiber attached to a distal end of the optical fiber. The optical fiber and the graded index fiber are together configured to provide a common path for optical radiation reflected from a reference interface at a distal end of the graded index fiber and from a target. The system further includes receiving electronics configured to receive the optical radiation reflected from the reference interface and the target and a processor to generate an image of the target based upon the optical radiation received by the receiving electronics.
This and other embodiments can include one or more of the following features. A secondary reflection of optical radiation from an interface between the optical fiber and the graded index fiber can be less than −60 dB. The reference interface can provide a reference reflection of between −28 and −42 dB. The system can further include an interface medium at the reference interface that can be in optical contact with the graded index fiber. A refractive index of the graded index fiber and a refractive index of the reference medium can be mismatched such that the receiving electronics operate in a total noise range that can be within 5 dB of the shot noise limit. The reference interface can be angled with respect to a longitudinal axis of the graded index fiber such the receiving electronics can operate in a total noise range that is within 5 dB of the shot noise limit. A surface of the interface medium that is closest to the target can be concave. The interface medium can be an adhesive. An outer diameter of the graded index fiber and a protective coating around the graded index fiber can be less than 0.01 inches.
In general, in one embodiment, a system for optical coherence tomography includes a source of optical radiation, an optical fiber, and a graded index fiber attached to a distal end of the optical fiber. The optical fiber and the graded index fiber are together configured to provide a common path for optical radiation reflected from a reference interface at a distal end of the graded index fiber and from a target. The system further includes receiving electronics configured to receive the optical radiation reflected from the reference interface and the target and a processor to generate an image of the target based upon the optical radiation received by the receiving electronics. A secondary reflection of optical radiation from an interface between the optical fiber and the graded index fiber is less than −60 dB.
This and other embodiments can include one or more of the following features. The reference interface can provide a reference reflection of between −28 and −42 dB. The system can further include an interface medium at the reference interface that can be in optical contact with the graded index fiber. A refractive index of the graded index fiber and a refractive index of the reference medium can be mismatched such that the receiving electronics operate in a total noise range that can be within 5 dB of the shot noise limit. The reference interface can be angled with respect to a longitudinal axis of the graded index fiber such the receiving electronics can operate in a total noise range that is within 5 dB of the shot noise limit. A surface of the interface medium that is closest to the target can be concave. The interface medium can be an adhesive. An outer diameter of the graded index fiber and a protective coating around the graded index fiber can be less than 0.01 inches.
In general, in one embodiment, a catheter for use with optical coherence tomography includes an elongate catheter body. The catheter includes an optical fiber in the elongate catheter body and a graded index fiber attached to a distal end of the optical fiber. The optical fiber and the graded index fiber are together configured to provide a common path for optical radiation reflected from a reference interface at a distal end of the graded index fiber and a target. A secondary reflection of optical radiation from an interface between the optical fiber and the graded index fiber can be less than −60 dB.
This and other embodiments can include one or more of the following features. The reference interface can provide a reference reflection of between −28 and −42 dB. A distance from an outer edge of the elongate catheter body and a focal point of the GRIN lens can be less than 1 mm. A distance from an outer edge of the elongate catheter body and a focal point of the GRIN lens can be less than 0.8 mm. The catheter can have a diameter of approximately 2 mm. The focal point can be configured to be in the target. The elongate catheter body can be an atherectomy catheter. The elongate catheter body can be an occlusion crossing catheter having a rotatable tip and a guidewire lumen therein.
In general, in one embodiment, a method of imaging a target includes inserting a catheter into a lumen of the target; transmitting optical radiation from a source through an optical fiber and a graded index fiber within the catheter; transmitting the optical radiation from the graded index fiber through an interface medium; transmitting the optical radiation reflected from the target and reflected from a reference interface along a common path in the graded index fiber and the optical fiber to a detector; and generating an imaging of the target based upon the reflected optical radiation.
This and other embodiments can include one or more of the following features. A distance from an edge of the catheter and a focal point of the graded index fiber can be less than 0.8 mm. The focal point can be in the target.
In general, in one embodiment, a method of making a graded index fiber for use with a common path optical coherence tomography system includes selecting a required distal angle of the graded index fiber such that a reference interface at the distal end of the graded index fiber will produce a reference reflection of between −28 and −42 dB; and polishing or cleaving the distal end of the graded index fiber to the selected angle within a tolerance of less than 0.2°.
This and other embodiments can include one or more of the following features. The method can further include splicing a graded index fiber to a distal end of a single mode optical fiber. The method can further include placing the distal end of the graded index fiber in optical contact with an interface medium to form the reference interface. The method can further include making an external surface of the interface medium concave.
The Optical Coherence Tomography (OCT) catheters and systems described herein are configured to provide image guided intra-vascular procedures that may be particularly useful for the diagnosis and/or treatment of arterial disease. The systems may include a catheter, an umbilical connection, and a console. The system uses OCT to form an image of the intravascular environment close to the catheter cutter. During intraluminal procedures, such as atherectomy, problems can arise as a result of failure to properly identify target tissue. By using a catheter having a common path optical fiber for OCT, proper identification of target tissue can be improved.
In general, the catheters described herein include a common-path system with a graded index (GRIN) fiber attached to the distal tip of a single mode optical fiber in the catheter so as to act as a lens for focusing light. The distal portion of the GRIN fiber is modified to provide a reference reflection between −28 dB and −45 dB, such as −28 dB and −42 dB, −32 dB and −45 dB, or −32 and −42 dB. In some embodiments, a secondary reflection of optical radiation from an interface between the optical fiber and the graded index fiber is configured to be less than −60 dB. An outer diameter of the graded index fiber and a protecting coating around the graded index fiber can be less than 0.01 inches. This common path OCT system with GRIN fiber advantageously achieves focusing of the light beam while still achieving the desired stable reference reflection and maintaining a small profile of the catheter.
Referring to
In the common-path OCT system 100, the index of refraction of the interface medium 106 is different than the index of refraction of the distal edge of the GRIN fiber 222. Because the indices of refraction of the interface medium 106 and the distal edge of the GRIN fiber 222 are different, a Fresnel reference reflection can be created, which can be used to generate the resulting OCT image. That is, part of the light from the light source will exit the GRIN fiber 222 to travel to the target 114 while part of the light will be reflected back from the distal end of the GRIN fiber 222 to form the reference reflection for the OCT system. Some of the light beam that exits the GRIN fiber 222 will encounter the target 114 and be reflected or scattered by the target 114, and some of this scattered light will, in turn, reenter the distal end of the GRIN fiber 222 and interfere with the reference reflection. The interference signal then travels back through the fiber 104. A Faraday isolation device 112, such as a Faraday Effect optical circulator, can be used to separate the paths of the outgoing light source signal (i.e., the light being sent to the target from the light source) and the interference signals returning from the distal end of the fiber. The separated interference signal can travel back to a detector 110 located at the proximal end of the optical fiber 104. The interference signal detected by the detector 110 can then be used create an image of the target, as described below.
Because the reflected or scattered target light in the OCT system 100 travels a longer distance than the Fresnel reflected reference light, the reflected or scattered target light can be displaced by frequency, phase and or time with respect to the reference beam. For example, if swept-source radiation is used, then the light from the target will be displaced in frequency. The difference in displacement in phase, time or frequency between the reflected or scattered target light and the reference light can be used to derive the path length difference between the end of the optical fiber tip and the light reflecting or light scattering region of the target. In the case of swept source OCT, the displacement is encoded as a beat frequency heterodyned on the carrier reference beam. Embodiments such as the system described with respect to
Referring to
The GRIN fiber 222, in contrast to standard lenses and even traditional GRIN lenses, can be specifically constructed such that the GRIN fiber 222 (including the core and any cladding, such as a cladding of less than 15 μm, e.g., approximately 12.5 μm) is approximately the same outer diameter as the optical fiber 104 (including the core 231 and cladding 233), thereby helping to maintain a low profile for the common path OCT system. For example, in one embodiment, the combined outer diameter of the optical fiber 104 and the GRIN fiber with a protective coating (as described further below) are both less than 0.01 inches, such as less than 0.08 inches, such as approximately 0.0065 inches with a protecting coating thickness of greater than or equal to 0.007 mm, such as 0.015 mm, 0.02 mm, or 0.022 mm. Advantageously, the GRIN fiber 222, in contrast to a larger focusing lens, can advantageously be substituted in place of a distal portion of an optical fiber in a catheter without having to make significant changes to the catheter design due to the relatively small diameter of the fiber.
Referring to
Referring back to
In some embodiments, as shown in
Referring back to
Noise in OCT systems comes from at least three sources: shot noise, thermal or Johnson noise, and residual intensity noise (RIN noise). There may additionally be noise from the analog-to-digital conversion process. RIN noise comes from noise intrinsic to the light source, tends to dominate at high reference powers, and can be limited by limiting the maximum laser light intensity, working with an alternative low RIN light source (non-laser), or by using balanced detection. Thermal (Johnson) noise tends to dominate at low reference power levels, and can be avoided by working at reference power levels yielding a DC photodiode current above that of the thermal noise floor.
Shot noise dominates in between RIN noise and thermal (Johnson) noise. Shot noise is caused by statistical fluctuations in the number of photons or electrons that carry a particular signal. For a well designed system, shot noise is the limiting factor in dynamic range. The indexes of refraction of the GRIN fiber 222 and the interface medium 106 can thus be chosen such that the OCT system 100 operates close to the shot noise limit.
The shot noise limit of a particular receiver is set by the responsivity of the photodetector, the detection bandwidth desired, and the reference DC power impinging on the detector element. An exemplary graph of a noise v. power is shown in
The shot noise limit is the area 301 at the bottom of the curve in
To determine the total power, Pout, that must be reflected from the interface 106 to obtain the desired Pdet, the losses of the detector 110 must be taken into account according to Equation 1:
Pdet=Pout(1−L) (equation 1)
where Pout is the power reflected from the reference interface and L is the sum of the optical losses from the distal end of the probe to the detector 110. Therefore, assuming that Pdet is equal to 0.2 μW (rounding from the 0.158 μW determined to place the noise as low to the shot noise limit as possible) and that the intermediate optical system operates at 90% efficiency such that L is 10%, then Pout is equal to 0.2 μW/(0.9)=0.2222 μW.
The forward power at the distal end of the GRIN fiber prior to entering the interface medium is given by Pin. In one exemplary embodiment, Pin can be equal to 10 mW.
Moreover, Pout and Pin can be used to determine the reflectivity of the reference interface 180, according to equation 2:
Pout=PinR2 (equation 2)
where R is the Fresnel coefficient of reflectivity. Therefore, assuming that Pout is 0.2222 μW and Pin is 10 mW (as described above), then R is equivalent to 0.004714.
Moreover, the Fresnel equation (shown by equation 3) governs the intensity of reflection from a normal or near normal interface:
where the index of refraction of the transparent medium is given by n2 and that of the core is n1.
If the distal end of the GRIN fiber 222 is kept polished such that it has a normal interface with the interface medium, then the refractive index of the GRIN lens, n1, will be fixed and can be assumed to be substantially equal to the refractive index at the center of the GRIN lens. For example, if the refractive index at the center of the GRIN lens is 1.4677, then the refractive index of the interface medium n2 would have to be 1.4816 or 1.4539, according to equation 3 above. Thus, an interface medium of either index will produce the desired reference reflection. In some embodiments, the medium with the higher index of refraction may be preferable as it may be more readily available and/or have better mechanical properties, such as tensile strength.
The interface medium used with system 100 can be, for example, an adhesive. Depending upon the required index of refraction, the interface medium can be, for example, M21-CL which is a thermal curing adhesive. Another exemplary interface medium is the Light Weld® UV curable photonics adhesive OP-4-20658, produced by Dymax corporation, Torrington Conn. This adhesive, which has a refractive index of 1.585 in the cured state, is a rigid clear UV-curable adhesive that can be applied in a liquid form, and which then cures to a rigid form within seconds of exposure to UV light. Another exemplary transparent medium is EpoTek OG127-4 or OG116, produced by Epoxy Technology, Billerica Mass. This has a refractive index of 1.602 in the cured state. Another exemplary transparent medium is Masterbond EP42HT-2, which has a cured refractive index of 1.61. Another exemplary transparent medium is Norland Optical Adhesive NOA-61, which has a refractive index of 1.56 upon curing.
If an interface medium having the exact refractive index desired cannot be found (for example because it does not have the proper tensile strength or is not biocompatible), an interface medium having a refractive index that is close can be selected and the power in, Pin, can be adjusted accordingly. Using the known r and the desired power at the detector, Pdet, the required power in Pin can then be determined according to equation 4:
Pdet=PinR2(1−L) (equation 4)
In some implementations, the interface medium can be applied in a semi-liquid state, such as by dispenser, ink jet deposition, spraying, painting, dipping, or other process. The medium may then be cured to a solid form, such as by UV curing, thermal curing, chemical curing, drying, or other process. Other processes, such as vacuum deposition of transparent medium or direct mechanical placement of the transparent medium may also be used.
The interface medium can have a minimum thickness (i.e. depth between the end of the optical fiber and the end of the interface medium) of at least
where λmin is the wavelength of light in the optical fiber. For a wavelength of over 1250 nm, this will be approximately 200 nm or greater. The interface medium can also have a thickness that is great enough to introduce an offset between the reference reflection and the minimum distance that the target can approach the distal exit face of the GRIN fiber 222.
Alternatively, if a particular interface medium is desired due, for example, to the adhesive properties and/or biocompatibility of the interface medium, then the desired reference reflection can be achieved by cleaving or polishing the distal end of the GRIN fiber at a particular angle. In this case, equation 5 governs the reflection from the surface assuming that the incident light is unpolarized and therefore contains an equal mix of s and p polarizations:
where Rs is the reflection coefficient caused by the s-polarized light and is determined by equation 6:
where is θi is the angle of incidence and θt is the angle of transmittance (see
Accordingly, if the refractive index of the medium, n2, is fixed because a particular medium is desired, then the Fresnel reflection can be adjusted by changing the cleave or polishing angle of the distal end of the GRIN fiber. In some embodiments, the cleave or polishing angle can be cleaved or polished to the desired angle within a tight tolerance, such as a tolerance (or variation from the desired angle) within less than 0.5°, less than 0.4°, less than 0.3°, or less than 0.2°, such as less than or equal to 0.15°. In contrast to standard single mode fibers, cleaving or polishing the distal end of the GRIN fiber within such tight tolerances is important to obtain the desired index of reflection because the back-reflection in GRIN fiber is much more sensitive to the cleave angle than the back-reflection in standard single-mode fiber.
Thus, as shown in
Once the approximate angles have been determined using the equations described herein, the polishing can be adjusted slightly to compensate for any loss of light caused by the interface between the GRIN fiber and the optical fiber. That is, the Fresnel equations described herein do not take into account the interface between the GRIN fiber and the optical fiber. If the distal end of the GRIN fiber is polished or cleaved at an angle, then the coupling efficiency of resulting beam of reflected light traveling through the GRIN fiber and into the Single Mode optical fiber may change. Thus, while the distal angle required can be approximately determined by the equations described herein, further adjustment may be required in order to achieve the desired reflection. Further, the tolerance on the set angle for required reference reflection is very high as a the magnitude of change in reference reflection is effected both by Fresnel Reflection and coupling efficiency of the light from GRIN fiber into the Single Mode optical fiber. In some embodiments, additional factors, such as the diameter of the GRIN fiber, can also be adjusted to achieve the desired reflection. The device described herein can thus include a GRIN fiber as a focusing element that generates a stable reference reflection at the distal tip of the GRIN fiber.
Referring to
Referring to
U.S. Provisional Patent Application No. 61/799,505, titled “OCCLUSION-CROSSING DEVICES”, filed Mar. 15, 2013; International Patent Application No. PCT/US2013/032679, titled “CHRONIC TOTAL OCCLUSION CROSSING DEVICES WITH IMAGING”, filed Mar. 15, 2013, Publication No. WO 2014/143064; U.S. patent application Ser. No. 12/829,277, titled “ATHERECTOMY CATHETER WITH LATERALLY-DISPLACEABLE TIP”, filed Jul. 1, 2010, U.S. Pat. No. 9,498,600; U.S. patent application Ser. No. 13/175,232, titled “ATHERECTOMY CATHETERS WITH LONGITUDINALLY DISPLACEABLE DRIVE SHAFTS”, filed Jul. 1, 2011, U.S. Pat. No. 9,345,510; U.S. patent application Ser. No. 13/654,357, titled “ATHERECTOMY CATHETERS AND NON-CONTACT ACTUATION MECHANISM FOR CATHETERS”, filed Oct. 17, 2012, Publication No. US-2013-0096589-A1; U.S. patent application Ser. No. 13/675,867, titled “OCCLUSION-CROSSING DEVICES, ATHERECTOMY DEVICES, AND IMAGING”, filed Nov. 13, 2012, U.S. Pat. No. 9,345,406; International Patent Application No. PCT/US2013/031901, titled “ATHERECTOMY CATHETERS WITH IMAGING”, filed Mar. 15, 2013, Publication No. WO 2013/172970; and International Patent Application No. PCT/US2013/032494, titled “BALLOON ATHERECTOMY CATHETERS WITH IMAGING”, filed Mar. 15, 2013, Publication No. WO 2014/039099, all of which are incorporated by reference in their entireties.
As shown in
Referring to
thick, where λmin is the wavelength of light in the optical fiber. For example, the metallic coating can be greater than about 2,800 Å thick.
Further, the surface of the silicon die 401 under the reflective coating 403 can be polished to less than 400 nm peak-to-peak roughness, such as better than 300 nm peak-to-peak roughness, for example about 200 nm peak-to-peak roughness. An adhesive, such as nickel, titanium, or chromium, can be used to adhere the gold coating to the silicon die. The adhesive can be between about 50 Å and 200 Å thick, such as about 100 Å thick. The reflective surface 180 of this configuration can be at least 95% reflective, such as 98% reflective.
The reflective surface 180 can be placed on a slope such that it is at an angle of between 30° and 60°, such as 45° with respect to a longitudinal axis 405 of the core of the optical fiber 104. Moreover, the reflective surface 180 can be configured such that the total distance that the light travels from the GRIN fiber 222 to the reflective surface 180 and out to the sample is between 100 and 400 μm, such as between 200 and 250 μm.
As shown in
The system described herein may be used to produce relatively narrow angle images of a portion of an interior lumen of a human body, such as the interior of a blood vessel. Looking at a section of a tissue through a single OCT optical fiber is limited in that the useful angle of view produced by a single OCT optical fiber is at most a few degrees. In order to produce a more medically useful panoramic view of a wide arc or swath from the interior of a blood vessel, such as 45°, 90°, 120°, or more, the catheter containing the optical fiber can be rotated.
The system described herein can produce images, e.g. images of tissue morphology, having an axial resolution of around 6-15 microns, e.g. 8-10 microns, and to depths of 1-2 mm depending on the optical properties of the sample being imaged. The axial resolution of the OCT system can be about ten times higher than that of a similar ultrasound system. The azimuthal resolution can be maintained to be less than 100 microns typically up to depths of 3-4 mm.
In some embodiments, the OCT system and catheter described herein can image up to 1-2 mm in depth with axial resolutions around 8-10 microns, sufficient to give the physician highly detailed images almost to the cellular organization level and visibility beyond the maximum cut range of the catheter. Moreover, the OCT atherectomy catheter described in can advantageously have imaging capability with crossing-profile impact that is much smaller than traditional OCT systems and ultrasound transducers.
In one example, an image-guided interventional catheter (e.g., an OCT catheter as described above) may be used to address unmet needs in peripheral and coronary artery disease (atherosclerosis). The system may include a console having a modest footprint and in a cath lab without need for extensive integration into cath lab systems. In some variations, the systems described herein may be integrated with other catheter (e.g., guidance, control, imaging) systems. The system may be configured to allow a procedure to start/proceed/finish under fluoro guidance in the event of a system failure. The system is also configured to be compatible with sterile procedures.
As mentioned above, the OCT systems described herein may allow real-time information on intravascular lesion morphology and device orientation in the vessel. This and other features may also allow improved navigation precision around complex anatomy (e.g., bifurcations, ostials, tortuosity, cutting on a curve, etc.), and around stent struts. The catheters may be safely used to traverse diseased tissue while reducing incidence of perforations and dissections potentially associated with a more aggressive treatment strategy. The systems may also provide immediate assessment of acute procedural success, and a reduction in procedure time compared to contemporary interventional techniques. The systems described herein may allow imaging of vessel wall morphology in real time and at a level of precision that could assist the physician in making a “diseased/not-diseased” determination.
In one example, the OCT system is configured to allow tissue morphology to be imaged in real time with resolution routinely around 8-10 microns, and to depths of 1-2 mm depending on the optical properties of the tissue. The axial resolution of OCT is sufficiently high that the images presented to the operator substantially resemble histology from optical microscopy, and are as a result more intuitively interpreted than ultrasound or MRI/CT images. The depth to which OCT can image through tissue with minimal to moderate lipid content is sufficient to give the physician visibility beyond the maximum proposed depth of cut for an atherectomy catheter, allowing the safety margins of the putative cut to be assessed.
As mentioned, OCT has several other technical and economic advantages for catheter applications. The impact on catheter crossing profile of the OCT optical fiber is much smaller than for even the smallest comparable ultrasound transducer. The axial resolution of OCT is typically 10× higher than ultrasound; this translates directly to image interpretability. The limited depth of penetration of typical OCT devices is not of primary concern in this application in many applications, because it is known from prior atherectomy procedures that substantial clinical benefit can be obtained by removing several hundred micron thicknesses of tissue. The depth of penetration may be matched to the expected maximum cut depth. Regions of particularly deep or thick tissue (target tissue to be removed) may be identified and treated serially or separately. For example, highly lipid-rich tissues (necrotic cores) appear as dark voids in OCT images, typically with bright caps.
The center wavelength for the optical system may be chosen to provide sufficient depth of penetration, as well as compatibility with the components of the system. For example, the OCT systems may use light that can be transmitted through fused silica fiber optics (where the primary investment in cost and quality has been made). The wavelength range to 250-2000 nm may be particularly useful. Single mode fibers can be readily obtained at any of these wavelength ranges, although wavelengths above 400 nm may be preferable. Below 250 nm air-guiding fibers can also be used. It may be easier to “see” through small annuli of either blood, saline or mixtures by restricting the scan range of the source to regions where hemoglobin and water do not strongly absorb light. This leads to the use of a “biological window” between about 800 nm and 1.4 microns.
The dominant mechanism restricting penetration depth in biological tissue when using ballistic optical scattering techniques is the photon scattering cross-section in the tissue. Higher scattering cross-sections causes fewer photons to traverse from source to target and back ballistically, that is with only one scattering event at the target leading to a reduction in useful signal. The scattering cross-section scales as an inverse power of wavelength over the 250-2000 nm range, transitioning from an exponent of −4 at shorter wavelengths to a smaller value at longer wavelengths. The value decreases monotonically going from short to longer wavelengths. Therefore, if it is desired to see deeper in tissue, the wavelength range of the source should be biased to longer wavelengths. Moving to longer wavelengths may, in some embodiments, require a more sophisticated laser source to achieve the same resolution compared to imaging at shorter wavelengths, however this is a soluble technical problem.
In some variations, the system takes advantage of the widespread availability of cheap, high quality parts. For example, fiber-based telecommunications has evolved at three specific center wavelength ranges; 800 (LAN only), 1310 (O-band) and 1550 nm (C-band). The systems described herein may use a center wavelength to 1310 nm, though this does not mean that the other two wavelength ranges could not be made to work. For example, the 800 nm center wavelength range is routinely used in ophthalmology, where depth of penetration can be sacrificed for tissue layer resolution and where fiber delivery is not a requirement (free-space optics may be used). In some variations, the system works in the telecommunications O-band. In practice the range of center wavelength is 1315-1340 nm may be dictated by the availability of suitable laser sources in the O-band.
There are three primary categories of source/detector combinations in OCT, namely Time-Domain, Spectral-Domain (Fourier Domain or Spectral Radar) and Swept Source OCT. The examples of OCT systems described herein are swept source OCT (SS-OCT), which allow for video-rate imaging, few or no moving parts, a simple optical system suitable for fiber implementation, imaging to depths greater than 1 mm, and insensitivity to the rigors of a mobile environment.
As discussed above, several interferometer configurations may be used. The systems described herein are Common Path Interferometry (CPI) systems. This has several advantages given the goal of catheter based imaging with cost-constrained capital equipment and disposable devices. The SS-OCT with CPI system described herein preserves the Fellgett Advantage. Fellgett's advantage or the multiplex advantage is an improvement in spectroscopic techniques that is gained when an interferometer is used instead of a monochromator or scanning delay line. The improvement arises because when an interferometer is employed, the radiation that would otherwise be partially or wholly rejected by the monochromator or scanning delay line in its path retains its original intensity. This results in greater efficiency. This embodiment contrasts with the other systems, in which only a small fraction of the laser power is useful at any given time. For example, the Lightlab™ M2 system uses TD-OCT with a scanning delay line, which is equivalent for the purposes of the Fellgett Advantage to a monochromator. Clinically, the Fellgett advantage impacts imaging speed (frame update rate), allowing significant improvements in video display rates which translate to a reduction in ambiguity in interpreting the image.
The CPI systems described herein also preserve the Jacquinot Advantage. The Jacquinot advantage states that in a lossless optical system, the brightness of the object equals the brightness of the image. Assuming that losses due the optical components are negligible, an interferometer's output will be nearly equal in intensity to the input intensity, thus making it easier to detect the signal. This translates directly to image quality, and a more interpretable image.
The CPI system as described herein therefore makes highly efficient use of the laser power. Light is either used for the reference reflection or impinges on the tissue and is used to create signal. No light is lost in attenuators or additional optical components or unused reciprocal paths. This efficient use of laser power is most apparent in the ability of the system to display clinically relevant images of the intravascular environment in real time, without the need for extensive post processing or even on-the-fly image correction.
Furthermore, these systems are “down-lead insensitive”, allowing the connection from catheter to console to be of almost arbitrary length without requiring a matched reference delay line to be shipped with each catheter. This minimizes the additional cost impact of the imaging components added to the catheter. It also allows a console component to be positioned almost anywhere, minimizing the potential disruption to work flow and minimizing the threat to a sterile field.
The systems described herein also minimize the number of optical components in the imaging system which could contribute to chromatic aberration. This minimization preserves the spectral fidelity of the laser source optimizing the layer resolution. This translates directly to image quality, and a more interpretable image.
The common-path systems described herein also have exceptional phase stability. Path length changes affecting the sample arm (temperature changes, stress-induced birefringence etc) also affect the reference arm identically. The distance from the ZPD (zero-pathlength difference) point (the reference plane) to the sample is physically fixed and is not subject to variability due to turbulence. This exceptional phase stability coupled with the exceptional phase stability of the OCT engine means that the Z-axis of the display (depth) has minimal jitter, in turn maximizing the real-time interpretability of the image. It also allows mathematical manipulation of the data that would otherwise be impossible. For example, one advantage of the systems described herein is the ability to perform pre-FFT averaging, which lowers the overall noise floor of the system again translating directly to image quality and interpretability.
In one example, the catheter is around 2 mm in diameter (7F compatible). In a saline-filled lumen, the system will be able to detect an interface (e.g., vessel wall) at 2 mm from the OD of the catheter. In this variation, the following parameters may be used for the catheter and system:
The detector may detect optical modulation on the carrier wave from DC to at least 10 MHz with no roll-off in sensitivity. To prevent aliasing (which complicates image interpretation) we may digitize the detector output at a minimum of 20 M-Samples/sec (Nyquist limit) to preserve interpretable real time imaging capability. We may thus capture at least 630 points per laser pulse at this digitizer rate to avoid undersampling the available laser bandwidth.
A practical resolution target is the intima of healthy coronary artery. The system resolution is capable of showing the intima (endothelial layer+internal elastic lamina) as a single sharp bright line on the display.
The system may have an impulse response of 8-10 microns. This resolution dictates the laser scan range requirements and the bandwidth requirements of all the optical components in the fiber harness through the equation:
Where δz is the axial resolution, λ is the wavelength, Δλ is the wavelength range over which the laser scans, n is the refractive index of the medium and the other symbols have their usual meaning. The origin of this relationship is the Heisenberg Uncertainty Principle. Several observations accrue from this equation.
If the laser scan range Δλ is not broad enough, δz (the resolution) is compromised and an image of a step refractive index discontinuity will be blurred out over many pixels. If any of the optical components in the system restrict (alternatively called clipping or vignetting) the effective bandwidth of the system is reduced and the resolution may suffer. Since the resolution equation has the center wavelength squared in the numerator, as we move to longer center wavelengths for the reasons described above, commensurately larger laser scan range may achieve equivalent axial resolution. Ophthalmology is routinely performed at 800 or 1000 nm center wavelength where there is no need to image deeply into the retina, but where the available lasers allow extremely high resolution of the layers of the retina (down to 1-2 microns thickness).
In some variations, the OCT system has a scan range of >100 nm. The theoretical resolution of this engine is 6.35 microns in a medium with a refractive index of 1.35. Stipulating that we digitize at least at the Nyquist limit, fully sample the scanned bandwidth, and that the rescaling procedure in the software does not distort the data, the theoretical resolution of this system is sufficient to show the intima of a healthy coronary artery at the impulse response limit.
The choice of 1310 nm as a center wavelength for the laser means that we may use standard commercial off-the-shelf telecommunications components which have guaranteed performance at this wavelength and for which standardized test protocols exist. Reasonable and customary incoming inspection procedures can be used to verify that the components going into the system will not deteriorate image quality.
As mentioned above, the system may include receiving electronics including a detector. Assuming that the operating center wavelength is 1315-1340 nm with a full-width half maximum responsivity of >100 nm, and that the detector operates as close as reasonably possible to the shot-noise limited regime, the system may have sufficient trans-impedance gain from the detector to allow the A/D card to operate at an input range where digitizer noise is not a dominant contributor to the noise floor of the system.
Manufacturing tolerances on the catheters will yield a range of distal tip reference reflection intensities. The detector may be configured or chosen so as not to saturate at the high manufacturing limit of the reference reflection power. In one example, the system uses a Fermionics FD80 photodiode in an FC receptacle package as the active element in the photodetector.
The system may also include a fiber harness designed to: 1) provide a low loss pathway from the laser to the catheter, 2) route signal light returning from the catheter to the detector, 3) allow the bleed-in of a red laser diode signal to allow rapid assessment of the integrity of the fiber from cable to distal tip, and 4) provide manufacturing, calibration and field service housekeeping signals to facilitate console production, validation and maintenance.
One primary component of the fiber harness may be a self-contained enclosure with bulkhead FC/APC receptacles on it and containing an optical circuit (such as the one shown in
In one example, the fiber harness may be connected as: #1 Incoming OCT source (e.g., Santec) Santec output connected here. #2 Diagnostic port (OSA/Photodiode/MZI Calibration); #3 Diagnostic port (OSA/Photodiode/MZI Calibration); #4 Connection to Detector; #5 Reflected FBG Marker (Time/Wavelength Calibration Point); #6 Connection to Catheter; #7 Transmitted FBG Signal (Photodiode scope trigger); #8 Connection to red laser source. Connections may be made with single mode fiber with a cut-off of <1260 nm. The inputs/outputs do not need to be optically isolated.
In some variations, an electrical harness may be used. The electrical harness may be configured to: 1) provide isolation for the various electrical components in the imaging system; 2) distribute 110V to the OCT engine, slave monitor and computer; 3) provide regulated isolated housekeeping power at appropriate voltages and amperages to the detector, red diode laser, catheter handle azimuthal position encoder; 4) send the video signal to the remote monitor; and 5) receive the catheter handle azimuthal angle encoder signal back to the console.
Line power may enter the console through a standard IEC60320 type C14 male power cord entry connector. The power cord used may be Hospital Grade and may have a standard IEC60320 type C13 female connector at the console end. An isolation transformer can distribute LINE power to the OCT engine, slave monitor and computer through IEC standard power cords.
The optical fiber may have a cut-off less than 1260 nm and have single mode performance between 1270 and 1380 nm (and be manufactured compatible with SMF-28 standards). The mechanical connections (pigtail and patch cable) may include a simplex cable, and an inner loose tube Teflon Aramid fiber inner annulus to prevent stretching. The outer Jacket may be 2 mm polyurethane. The connector may be a Diamond E2108.6 connector with a 0.25 dB maximum insertion loss and a −65 dB maximum return loss.
The distal tip reference reflection (mirror) may include at least one (1) reflective interface, and may have a return loss of −33.5 dB (Nominal (31-35 dB)). There may be 200-250 microns solid transparent offset from interface to minimum tissue approach point. Interceding optical discontinuities between console and catheter distal tip may be kept to less than 65 dB return loss maximum for any individual surface. The number of reflective interfaces separated by less than 8 mm may be minimized. The parameters above are exemplary only, and may be varied as understood by those of skill in the art, while still remaining in the spirit of the invention as described herein.
The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. Other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is in fact disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising”, when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements, these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately”, even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical range recited herein is intended to include all sub-ranges subsumed therein.
This application is a continuation of U.S. patent application Ser. No. 15/419,815, titled “OPTICAL COHERENCE TOMOGRAPHY WITH GRADED INDEX FIBER FOR BIOLOGICAL IMAGING,” filed Jan. 30, 2017, now U.S. Pat. No. 10,952,615, which is a continuation of U.S. patent application Ser. No. 14/400,140, titled “OPTICAL COHERENCE TOMOGRAPHY WITH GRADED INDEX FIBER FOR BIOLOGICAL IMAGING”, filed Nov. 10, 2014, now U.S. Pat. No. 9,557,156, which is a 35 U.S.C. § 371 national phase application of International Patent Application No. PCT/US2013/031951, titled “OPTICAL COHERENCE TOMOGRAPHY WITH GRADED INDEX FIBER FOR BIOLOGICAL IMAGING”, filed Mar. 15, 2013, Publication No. WO 2013/172972, which claims priority to U.S. Provisional Patent Application No. 61/646,783, titled “OPTICAL COHERENCE TOMOGRAPHY WITH GRADED INDEX FIBER FOR BIOLOGICAL IMAGING”, filed May 14, 2012, each of which is incorporated by reference in its entirety. This application may be related to U.S. patent application Ser. No. 12/790,703, titled “OPTICAL COHERENCE TOMOGRAPHY FOR BIOLOGICAL IMAGING”, filed May 28, 2010, Publication No. US-2010-0305452-A1, which is incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3367727 | Ward et al. | Feb 1968 | A |
3908637 | Doroshow | Sep 1975 | A |
4178935 | Gekhaman et al. | Dec 1979 | A |
4487206 | Aagard | Dec 1984 | A |
4527553 | Upsher | Jul 1985 | A |
4552554 | Gould et al. | Nov 1985 | A |
4578061 | Lemelson | Mar 1986 | A |
4611600 | Cohen | Sep 1986 | A |
4621353 | Hazel et al. | Nov 1986 | A |
4639091 | Huignard et al. | Jan 1987 | A |
4651753 | Lifton | Mar 1987 | A |
4654024 | Crittenden et al. | Mar 1987 | A |
4681106 | Kensey et al. | Jul 1987 | A |
4686982 | Nash | Aug 1987 | A |
4691708 | Kane | Sep 1987 | A |
4729763 | Henrie | Mar 1988 | A |
4771774 | Simpson et al. | Sep 1988 | A |
4781186 | Simpson et al. | Nov 1988 | A |
4841977 | Griffith et al. | Jun 1989 | A |
4857046 | Stevens et al. | Aug 1989 | A |
4920961 | Grossi | May 1990 | A |
4926858 | Gifford, III et al. | May 1990 | A |
5000185 | Yock | Mar 1991 | A |
5002560 | Machold et al. | Mar 1991 | A |
5018529 | Tenerz et al. | May 1991 | A |
5041082 | Shiber | Aug 1991 | A |
5047040 | Simpson et al. | Sep 1991 | A |
5085662 | Willard | Feb 1992 | A |
5099850 | Matsui et al. | Mar 1992 | A |
5178153 | Einzig | Jan 1993 | A |
5182291 | Gubin et al. | Jan 1993 | A |
5190050 | Nitzsche | Mar 1993 | A |
5192291 | Pannek, Jr. | Mar 1993 | A |
5312415 | Palermo | May 1994 | A |
5312425 | Evans et al. | May 1994 | A |
5321501 | Swanson et al. | Jun 1994 | A |
5333142 | Scheps | Jul 1994 | A |
5358472 | Vance et al. | Oct 1994 | A |
5366464 | Belknap | Nov 1994 | A |
5372601 | Lary | Dec 1994 | A |
5383460 | Jang et al. | Jan 1995 | A |
5383467 | Auer et al. | Jan 1995 | A |
5425273 | Chevalier | Jun 1995 | A |
5425371 | Mischenko | Jun 1995 | A |
5429136 | Milo et al. | Jul 1995 | A |
5431673 | Summers et al. | Jul 1995 | A |
5437284 | Trimble | Aug 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
5459570 | Swanson et al. | Oct 1995 | A |
5460168 | Masubuchi et al. | Oct 1995 | A |
5465147 | Swanson | Nov 1995 | A |
5507725 | Savage et al. | Apr 1996 | A |
5507760 | Wynne et al. | Apr 1996 | A |
5507795 | Chiang et al. | Apr 1996 | A |
5517998 | Madison | May 1996 | A |
5556405 | Lary | Sep 1996 | A |
5607394 | Andersen et al. | Mar 1997 | A |
5613981 | Boyle et al. | Mar 1997 | A |
5620426 | Braithwaite | Apr 1997 | A |
5632754 | Farley | May 1997 | A |
5632755 | Nordgren et al. | May 1997 | A |
5674232 | Halliburton | Oct 1997 | A |
5681336 | Clement | Oct 1997 | A |
5690634 | Muller et al. | Nov 1997 | A |
5722403 | McGee et al. | Mar 1998 | A |
5728148 | Bostrom et al. | Mar 1998 | A |
5749846 | Edwards et al. | May 1998 | A |
5795295 | Hellmuth et al. | Aug 1998 | A |
5807339 | Bostrom et al. | Sep 1998 | A |
5830145 | Tenhoff | Nov 1998 | A |
5836957 | Schulz et al. | Nov 1998 | A |
5843050 | Jones et al. | Dec 1998 | A |
5843103 | Wolfman | Dec 1998 | A |
5851212 | Zirps et al. | Dec 1998 | A |
5868778 | Gershony et al. | Feb 1999 | A |
5872879 | Hamm | Feb 1999 | A |
5904651 | Swansori et al. | May 1999 | A |
5907425 | Dickensheets et al. | May 1999 | A |
5935075 | Casscells et al. | Aug 1999 | A |
5935139 | Bates | Aug 1999 | A |
5938602 | Lloyd | Aug 1999 | A |
5938671 | Katoh et al. | Aug 1999 | A |
5951482 | Winston et al. | Sep 1999 | A |
5951581 | Saadat et al. | Sep 1999 | A |
5951583 | Jensen et al. | Sep 1999 | A |
5956355 | Swanson | Sep 1999 | A |
5957952 | Gershony et al. | Sep 1999 | A |
5987995 | Sawatari et al. | Nov 1999 | A |
5997558 | Nash | Dec 1999 | A |
6001112 | Taylor | Dec 1999 | A |
6007530 | Dornhofer et al. | Dec 1999 | A |
6010449 | Selmon et al. | Jan 2000 | A |
6013072 | Winston | Jan 2000 | A |
6017359 | Gershony et al. | Jan 2000 | A |
6027514 | Stine et al. | Feb 2000 | A |
6032673 | Savage et al. | Mar 2000 | A |
6048349 | Winston et al. | Apr 2000 | A |
6080170 | Nash et al. | Jun 2000 | A |
6106515 | Winston et al. | Aug 2000 | A |
6110164 | Vidlund | Aug 2000 | A |
6120515 | Rogers et al. | Sep 2000 | A |
6120516 | Selmon et al. | Sep 2000 | A |
6134002 | Stimson et al. | Oct 2000 | A |
6134003 | Teamey et al. | Oct 2000 | A |
6152938 | Curry | Nov 2000 | A |
6152951 | Hashimoto et al. | Nov 2000 | A |
6160826 | Swanson et al. | Dec 2000 | A |
6175669 | Colston et al. | Jan 2001 | B1 |
6176871 | Pathak et al. | Jan 2001 | B1 |
6183432 | Milo | Feb 2001 | B1 |
6193676 | Winston et al. | Feb 2001 | B1 |
6206898 | Honeycutt et al. | Mar 2001 | B1 |
6228076 | Winston et al. | May 2001 | B1 |
6241744 | Imran et al. | Jun 2001 | B1 |
6283957 | Hashimoto et al. | Sep 2001 | B1 |
6285903 | Rosenthal et al. | Sep 2001 | B1 |
6290668 | Gregory et al. | Sep 2001 | B1 |
6294775 | Seibel et al. | Sep 2001 | B1 |
6299622 | Snow et al. | Oct 2001 | B1 |
6307985 | Murakami et al. | Oct 2001 | B1 |
6375615 | Flaherty et al. | Apr 2002 | B1 |
6402719 | Ponzi et al. | Jun 2002 | B1 |
6416527 | Berg et al. | Jul 2002 | B1 |
6445939 | Swanson et al. | Sep 2002 | B1 |
6445944 | Ostrovsky | Sep 2002 | B1 |
6447525 | Follmer et al. | Sep 2002 | B2 |
6451009 | Dasilva et al. | Sep 2002 | B1 |
6451036 | Heitzmann et al. | Sep 2002 | B1 |
6454717 | Pantages et al. | Sep 2002 | B1 |
6454779 | Taylor | Sep 2002 | B1 |
6482216 | Hiblar et al. | Nov 2002 | B1 |
6482217 | Pintor et al. | Nov 2002 | B1 |
6485413 | Boppart et al. | Nov 2002 | B1 |
6497649 | Parker et al. | Dec 2002 | B2 |
6501551 | Teamey et al. | Dec 2002 | B1 |
6503261 | Bruneau et al. | Jan 2003 | B1 |
6511458 | Milo et al. | Jan 2003 | B2 |
6517528 | Pantages et al. | Feb 2003 | B1 |
6542665 | Reed et al. | Apr 2003 | B2 |
6544230 | Flaherty et al. | Apr 2003 | B1 |
6546272 | MacKinnon et al. | Apr 2003 | B1 |
6551302 | Rosinko et al. | Apr 2003 | B1 |
6563105 | Seibel et al. | May 2003 | B2 |
6564087 | Pitris et al. | May 2003 | B1 |
6565588 | Clement et al. | May 2003 | B1 |
6572563 | Ouchi et al. | Jun 2003 | B2 |
6572643 | Gharibadeh | Jun 2003 | B1 |
6575995 | Huter et al. | Jun 2003 | B1 |
6579298 | Bruneau et al. | Jun 2003 | B1 |
6599296 | Gillick et al. | Jul 2003 | B1 |
6615071 | Casscells, III et al. | Sep 2003 | B1 |
6629953 | Boyd | Oct 2003 | B1 |
6638233 | Corvi et al. | Oct 2003 | B2 |
6645217 | MacKinnon et al. | Nov 2003 | B1 |
6657727 | Izatt et al. | Dec 2003 | B1 |
6666874 | Heitzmann et al. | Dec 2003 | B2 |
6673042 | Samson et al. | Jan 2004 | B1 |
6687010 | Horii | Feb 2004 | B1 |
6728571 | Barbato | Apr 2004 | B1 |
D489973 | Root et al. | May 2004 | S |
6730063 | Delaney et al. | May 2004 | B2 |
6758854 | Butler et al. | Jul 2004 | B1 |
6760112 | Reed et al. | Jul 2004 | B2 |
6800085 | Selmon et al. | Oct 2004 | B2 |
6818001 | Wulfman et al. | Nov 2004 | B2 |
6824550 | Noriega et al. | Nov 2004 | B1 |
6830577 | Nash et al. | Dec 2004 | B2 |
6845190 | Smithwick et al. | Jan 2005 | B1 |
6852109 | Winston et al. | Feb 2005 | B2 |
6853457 | Bjarklev et al. | Feb 2005 | B2 |
6856712 | Fauver et al. | Feb 2005 | B2 |
6867753 | Chinthammit et al. | Mar 2005 | B2 |
6879851 | McNamara et al. | Apr 2005 | B2 |
6947787 | Webler | Sep 2005 | B2 |
6961123 | Wang et al. | Nov 2005 | B1 |
6970732 | Winston et al. | Nov 2005 | B2 |
6975898 | Seibel | Dec 2005 | B2 |
7068878 | Crossman-Bosworth et al. | Jun 2006 | B2 |
7074231 | Jang | Jul 2006 | B2 |
7126693 | Everett et al. | Oct 2006 | B2 |
7172610 | Heitzmann et al. | Feb 2007 | B2 |
7242480 | Alphonse | Jul 2007 | B2 |
7261687 | Yang | Aug 2007 | B2 |
7288087 | Winston et al. | Oct 2007 | B2 |
7291146 | Steinke et al. | Nov 2007 | B2 |
7297131 | Nita | Nov 2007 | B2 |
7311723 | Seibel | Dec 2007 | B2 |
7344546 | Wulfman et al. | Mar 2008 | B2 |
7366376 | Shishkov et al. | Apr 2008 | B2 |
7382949 | Bouma et al. | Jun 2008 | B2 |
7426036 | Feldchtein et al. | Sep 2008 | B2 |
7428001 | Schowengerdt et al. | Sep 2008 | B2 |
7428053 | Feldchtein et al. | Sep 2008 | B2 |
7455649 | Root et al. | Nov 2008 | B2 |
7474407 | Gutin | Jan 2009 | B2 |
7485127 | Nistal | Feb 2009 | B2 |
7488340 | Kauphusman et al. | Feb 2009 | B2 |
7530948 | Seibel et al. | May 2009 | B2 |
7530976 | MacMahon et al. | May 2009 | B2 |
7538859 | Teamey et al. | May 2009 | B2 |
7538886 | Feldchtein | May 2009 | B2 |
7539362 | Teramura | May 2009 | B2 |
7542145 | Toida et al. | Jun 2009 | B2 |
7544162 | Ohkubo | Jun 2009 | B2 |
7545504 | Buckland et al. | Jun 2009 | B2 |
7555333 | Wang et al. | Jun 2009 | B2 |
7577471 | Camus et al. | Aug 2009 | B2 |
7583872 | Seibel et al. | Sep 2009 | B2 |
7616986 | Seibel et al. | Nov 2009 | B2 |
7637885 | Maschke | Dec 2009 | B2 |
7674253 | Fisher et al. | Mar 2010 | B2 |
7682319 | Martin et al. | Mar 2010 | B2 |
7706863 | Imanishi et al. | Apr 2010 | B2 |
7728985 | Feldchtein et al. | Jun 2010 | B2 |
7729745 | Maschke | Jun 2010 | B2 |
7734332 | Sher | Jun 2010 | B2 |
7738945 | Fauver et al. | Jun 2010 | B2 |
7753852 | Maschke | Jul 2010 | B2 |
7771425 | Dycus et al. | Aug 2010 | B2 |
7776062 | Bessellink et al. | Aug 2010 | B2 |
7785286 | Magnin et al. | Aug 2010 | B2 |
7813609 | Petersen et al. | Oct 2010 | B2 |
7821643 | Amazeen et al. | Oct 2010 | B2 |
7824089 | Charles | Nov 2010 | B2 |
7840283 | Bush et al. | Nov 2010 | B1 |
7944568 | Teramura et al. | May 2011 | B2 |
7952718 | Li et al. | May 2011 | B2 |
7972299 | Carter et al. | Jul 2011 | B2 |
8002763 | Berthiaume et al. | Aug 2011 | B2 |
8059274 | Splinter | Nov 2011 | B2 |
8062316 | Patel et al. | Nov 2011 | B2 |
8068921 | Prakash et al. | Nov 2011 | B2 |
8313493 | Fisher | Nov 2012 | B2 |
8361097 | Patel et al. | Jan 2013 | B2 |
8548571 | He et al. | Oct 2013 | B2 |
8548603 | Swoyer et al. | Oct 2013 | B2 |
8632557 | Thatcher et al. | Jan 2014 | B2 |
8644913 | Simpson et al. | Feb 2014 | B2 |
8647335 | Markus | Feb 2014 | B2 |
8696695 | Patel et al. | Apr 2014 | B2 |
8911459 | Simpson et al. | Dec 2014 | B2 |
9119662 | Moberg | Sep 2015 | B2 |
9125562 | Spencer et al. | Sep 2015 | B2 |
9333007 | Escudero et al. | May 2016 | B2 |
9345398 | Tachibana et al. | May 2016 | B2 |
9345406 | Spencer et al. | May 2016 | B2 |
9345510 | Patel et al. | May 2016 | B2 |
9345511 | Smith et al. | May 2016 | B2 |
9351757 | Kusleika | May 2016 | B2 |
9498247 | Patel et al. | Nov 2016 | B2 |
9498600 | Rosenthal et al. | Nov 2016 | B2 |
9557156 | Kankaria | Jan 2017 | B2 |
9572492 | Simpson et al. | Feb 2017 | B2 |
9579157 | Moberg | Feb 2017 | B2 |
9592075 | Simpson et al. | Mar 2017 | B2 |
9642646 | Patel et al. | May 2017 | B2 |
9788790 | Black et al. | Oct 2017 | B2 |
9854979 | Smith et al. | Jan 2018 | B2 |
9918734 | Patel et al. | Mar 2018 | B2 |
9949754 | Newhauser et al. | Apr 2018 | B2 |
10052125 | Rosenthal et al. | Aug 2018 | B2 |
10130386 | Simpson et al. | Nov 2018 | B2 |
10244934 | Tachibana et al. | Apr 2019 | B2 |
10335173 | Carver et al. | Jul 2019 | B2 |
10342491 | Black et al. | Jul 2019 | B2 |
10349974 | Patel et al. | Jul 2019 | B2 |
10357277 | Patel et al. | Jul 2019 | B2 |
10363062 | Spencer et al. | Jul 2019 | B2 |
10406316 | Garvey et al. | Sep 2019 | B2 |
10470795 | Patel et al. | Nov 2019 | B2 |
10548478 | Simpson et al. | Feb 2020 | B2 |
10568520 | Patel et al. | Feb 2020 | B2 |
10568655 | Simpson et al. | Feb 2020 | B2 |
10722121 | Smith et al. | Jul 2020 | B2 |
10729326 | Spencer et al. | Aug 2020 | B2 |
10860484 | Simpson et al. | Dec 2020 | B2 |
10869685 | Patel et al. | Dec 2020 | B2 |
10932670 | Smith et al. | Mar 2021 | B2 |
10952615 | Kankaria | Mar 2021 | B2 |
10952763 | Newhauser et al. | Mar 2021 | B2 |
11033190 | Patel et al. | Jun 2021 | B2 |
20010005788 | MoGuckin, Jr. | Jun 2001 | A1 |
20010020126 | Swanson et al. | Sep 2001 | A1 |
20020019644 | Hastings et al. | Feb 2002 | A1 |
20020072706 | Hiblar et al. | Jun 2002 | A1 |
20020082585 | Carroll et al. | Jun 2002 | A1 |
20020082626 | Donohoe et al. | Jun 2002 | A1 |
20020097490 | Jung et al. | Jul 2002 | A1 |
20020111548 | Swanson et al. | Aug 2002 | A1 |
20020115931 | Strauss et al. | Aug 2002 | A1 |
20020147459 | Bashiri et al. | Oct 2002 | A1 |
20020158547 | Wood | Oct 2002 | A1 |
20030002038 | Mawatari | Jan 2003 | A1 |
20030028100 | Teamey et al. | Feb 2003 | A1 |
20030032880 | Moore | Feb 2003 | A1 |
20030045835 | Anderson et al. | Mar 2003 | A1 |
20030095248 | Frot | May 2003 | A1 |
20030097044 | Rovegno | May 2003 | A1 |
20030120150 | Govari | Jun 2003 | A1 |
20030120295 | Simpson et al. | Jun 2003 | A1 |
20030125756 | Shturman et al. | Jul 2003 | A1 |
20030125757 | Patel et al. | Jul 2003 | A1 |
20030125758 | Simpson et al. | Jul 2003 | A1 |
20030139751 | Evans et al. | Jul 2003 | A1 |
20030181855 | Simpson et al. | Sep 2003 | A1 |
20040002650 | Mandrusov et al. | Jan 2004 | A1 |
20040039371 | Tockman et al. | Feb 2004 | A1 |
20040057667 | Yamada et al. | Mar 2004 | A1 |
20040059257 | Gaber | Mar 2004 | A1 |
20040082850 | Bonner et al. | Apr 2004 | A1 |
20040092915 | Levatter | May 2004 | A1 |
20040093001 | Hamada | May 2004 | A1 |
20040147934 | Kiester | Jul 2004 | A1 |
20040167553 | Simpson et al. | Aug 2004 | A1 |
20040167554 | Simpson et al. | Aug 2004 | A1 |
20040181249 | Torrance et al. | Sep 2004 | A1 |
20040186368 | Ramzipoor et al. | Sep 2004 | A1 |
20040193140 | Griffin et al. | Sep 2004 | A1 |
20040202418 | Ghiron et al. | Oct 2004 | A1 |
20040220519 | Wulfman et al. | Nov 2004 | A1 |
20040230212 | Wulfman | Nov 2004 | A1 |
20040230213 | Wulfman et al. | Nov 2004 | A1 |
20040236312 | Nistal et al. | Nov 2004 | A1 |
20040243162 | Wulfman et al. | Dec 2004 | A1 |
20040254599 | Lipoma et al. | Dec 2004 | A1 |
20040260236 | Manning et al. | Dec 2004 | A1 |
20050020925 | Kleen et al. | Jan 2005 | A1 |
20050021075 | Bonnette et al. | Jan 2005 | A1 |
20050027199 | Clarke | Feb 2005 | A1 |
20050043614 | Huizenga et al. | Feb 2005 | A1 |
20050054947 | Goldenberg | Mar 2005 | A1 |
20050075660 | Chu et al. | Apr 2005 | A1 |
20050085708 | Fauver et al. | Apr 2005 | A1 |
20050085721 | Fauver et al. | Apr 2005 | A1 |
20050105097 | Fang-Yen et al. | May 2005 | A1 |
20050141843 | Warden et al. | Jun 2005 | A1 |
20050154407 | Simpson | Jul 2005 | A1 |
20050159712 | Andersen | Jul 2005 | A1 |
20050159731 | Lee | Jul 2005 | A1 |
20050171478 | Selmon et al. | Aug 2005 | A1 |
20050177068 | Simpson | Aug 2005 | A1 |
20050182295 | Soper et al. | Aug 2005 | A1 |
20050187571 | Maschke | Aug 2005 | A1 |
20050192496 | Maschke | Sep 2005 | A1 |
20050197623 | Leeflang et al. | Sep 2005 | A1 |
20050201662 | Petersen et al. | Sep 2005 | A1 |
20050203553 | Maschke | Sep 2005 | A1 |
20050222519 | Simpson | Oct 2005 | A1 |
20050222663 | Simpson et al. | Oct 2005 | A1 |
20050251116 | Steinke et al. | Nov 2005 | A1 |
20060011820 | Chow-Shing et al. | Jan 2006 | A1 |
20060032508 | Simpson | Feb 2006 | A1 |
20060046235 | Alexander | Mar 2006 | A1 |
20060049587 | Cornwell | Mar 2006 | A1 |
20060064009 | Webler et al. | Mar 2006 | A1 |
20060084911 | Belef et al. | Apr 2006 | A1 |
20060109478 | Teamey et al. | May 2006 | A1 |
20060135870 | Webler | Jun 2006 | A1 |
20060173475 | Lafontaine et al. | Aug 2006 | A1 |
20060229646 | Sparks | Oct 2006 | A1 |
20060229659 | Gifford et al. | Oct 2006 | A1 |
20060235262 | Amal et al. | Oct 2006 | A1 |
20060235366 | Simpson | Oct 2006 | A1 |
20060236019 | Soito et al. | Oct 2006 | A1 |
20060239982 | Simpson | Oct 2006 | A1 |
20060241503 | Schmitt | Oct 2006 | A1 |
20060244973 | Yun et al. | Nov 2006 | A1 |
20060252993 | Freed et al. | Nov 2006 | A1 |
20060264741 | Prince | Nov 2006 | A1 |
20060264743 | Kleen et al. | Nov 2006 | A1 |
20060264907 | Eskridge et al. | Nov 2006 | A1 |
20070010840 | Rosenthal et al. | Jan 2007 | A1 |
20070015969 | Feldman et al. | Jan 2007 | A1 |
20070015979 | Redel | Jan 2007 | A1 |
20070035855 | Dickensheets | Feb 2007 | A1 |
20070038061 | Huennekens et al. | Feb 2007 | A1 |
20070038125 | Kleen et al. | Feb 2007 | A1 |
20070038173 | Simpson | Feb 2007 | A1 |
20070050019 | Hyde | Mar 2007 | A1 |
20070078469 | Soito et al. | Apr 2007 | A1 |
20070078500 | Ryan et al. | Apr 2007 | A1 |
20070081166 | Brown et al. | Apr 2007 | A1 |
20070088230 | Terashi et al. | Apr 2007 | A1 |
20070106155 | Goodnow et al. | May 2007 | A1 |
20070135712 | Maschke | Jun 2007 | A1 |
20070167710 | Unal et al. | Jul 2007 | A1 |
20070196926 | Soito et al. | Aug 2007 | A1 |
20070213618 | Li et al. | Sep 2007 | A1 |
20070219484 | Straub | Sep 2007 | A1 |
20070250080 | Jones et al. | Oct 2007 | A1 |
20070255252 | Mehta | Nov 2007 | A1 |
20070270647 | Nahen et al. | Nov 2007 | A1 |
20070276419 | Rosenthal | Nov 2007 | A1 |
20070288036 | Seshadri | Dec 2007 | A1 |
20070299309 | Seibel et al. | Dec 2007 | A1 |
20080004643 | To et al. | Jan 2008 | A1 |
20080004644 | To et al. | Jan 2008 | A1 |
20080004645 | To et al. | Jan 2008 | A1 |
20080004646 | To et al. | Jan 2008 | A1 |
20080015491 | Bei et al. | Jan 2008 | A1 |
20080015618 | Sonnenschein et al. | Jan 2008 | A1 |
20080027334 | Langston | Jan 2008 | A1 |
20080033396 | Danek et al. | Feb 2008 | A1 |
20080045986 | To et al. | Feb 2008 | A1 |
20080049234 | Seitz | Feb 2008 | A1 |
20080058629 | Seibel et al. | Mar 2008 | A1 |
20080065124 | Olson | Mar 2008 | A1 |
20080065125 | Olson | Mar 2008 | A1 |
20080065205 | Nguyen et al. | Mar 2008 | A1 |
20080095421 | Sun et al. | Apr 2008 | A1 |
20080103439 | Torrance et al. | May 2008 | A1 |
20080103446 | Torrance et al. | May 2008 | A1 |
20080103516 | Wulfman et al. | May 2008 | A1 |
20080132929 | O'Sullivan et al. | Jun 2008 | A1 |
20080139897 | Ainsworth et al. | Jun 2008 | A1 |
20080146942 | Dala-Krishna | Jun 2008 | A1 |
20080147000 | Seibel et al. | Jun 2008 | A1 |
20080154293 | Taylor et al. | Jun 2008 | A1 |
20080154296 | Taylor et al. | Jun 2008 | A1 |
20080177138 | Courtney et al. | Jul 2008 | A1 |
20080186501 | Xie | Aug 2008 | A1 |
20080207996 | Tsai | Aug 2008 | A1 |
20080221388 | Seibel et al. | Sep 2008 | A1 |
20080228033 | Tumlinson et al. | Sep 2008 | A1 |
20080243030 | Seibel et al. | Oct 2008 | A1 |
20080243031 | Seibel et al. | Oct 2008 | A1 |
20080262312 | Carroll et al. | Oct 2008 | A1 |
20080275485 | Bonnette et al. | Nov 2008 | A1 |
20090018565 | To et al. | Jan 2009 | A1 |
20090018566 | Escudero et al. | Jan 2009 | A1 |
20090018567 | Escudero et al. | Jan 2009 | A1 |
20090024084 | Khosla et al. | Jan 2009 | A1 |
20090024085 | To et al. | Jan 2009 | A1 |
20090024191 | Seibel et al. | Jan 2009 | A1 |
20090028407 | Seibel et al. | Jan 2009 | A1 |
20090028507 | Jones et al. | Jan 2009 | A1 |
20090043191 | Castella et al. | Feb 2009 | A1 |
20090073444 | Wang | Mar 2009 | A1 |
20090076447 | Casas et al. | Mar 2009 | A1 |
20090093764 | Pfeffer et al. | Apr 2009 | A1 |
20090099641 | Wu et al. | Apr 2009 | A1 |
20090125019 | Douglass et al. | May 2009 | A1 |
20090135280 | Johnston et al. | May 2009 | A1 |
20090137893 | Seibel et al. | May 2009 | A1 |
20090152664 | Tian et al. | Jun 2009 | A1 |
20090185135 | Volk | Jul 2009 | A1 |
20090196477 | Cense et al. | Aug 2009 | A1 |
20090196554 | Irisawa | Aug 2009 | A1 |
20090198125 | Nakabayashi et al. | Aug 2009 | A1 |
20090208143 | Yoon et al. | Aug 2009 | A1 |
20090216180 | Lee et al. | Aug 2009 | A1 |
20090221904 | Shealy et al. | Sep 2009 | A1 |
20090221920 | Boppart et al. | Sep 2009 | A1 |
20090234220 | Maschke | Sep 2009 | A1 |
20090235396 | Wang et al. | Sep 2009 | A1 |
20090244485 | Walsh et al. | Oct 2009 | A1 |
20090244547 | Ozawa | Oct 2009 | A1 |
20090264826 | Thompson | Oct 2009 | A1 |
20090268159 | Xu et al. | Oct 2009 | A1 |
20090284749 | Johnson et al. | Nov 2009 | A1 |
20090292199 | Bielewicz et al. | Nov 2009 | A1 |
20090306520 | Schmitt et al. | Dec 2009 | A1 |
20090316116 | Melville et al. | Dec 2009 | A1 |
20090318862 | Ali et al. | Dec 2009 | A1 |
20100004544 | Toida | Jan 2010 | A1 |
20100021926 | Noordin | Jan 2010 | A1 |
20100049225 | To et al. | Feb 2010 | A1 |
20100080016 | Fukui et al. | Apr 2010 | A1 |
20100082000 | Honeck et al. | Apr 2010 | A1 |
20100125253 | Olson | May 2010 | A1 |
20100130996 | Doud et al. | May 2010 | A1 |
20100198081 | Hanlin et al. | Aug 2010 | A1 |
20100217245 | Prescott | Aug 2010 | A1 |
20100241147 | Maschke | Sep 2010 | A1 |
20100253949 | Adler et al. | Oct 2010 | A1 |
20100292539 | Lankenau et al. | Nov 2010 | A1 |
20100292721 | Moberg | Nov 2010 | A1 |
20100312263 | Moberg et al. | Dec 2010 | A1 |
20100317973 | Nita | Dec 2010 | A1 |
20100324472 | Wulfman | Dec 2010 | A1 |
20110023617 | Yu et al. | Feb 2011 | A1 |
20110028977 | Rauscher et al. | Feb 2011 | A1 |
20110040238 | Wulfman et al. | Feb 2011 | A1 |
20110058250 | Liu et al. | Mar 2011 | A1 |
20110060186 | Tilson et al. | Mar 2011 | A1 |
20110071401 | Hastings et al. | Mar 2011 | A1 |
20110092955 | Purdy et al. | Apr 2011 | A1 |
20110106004 | Eubanks et al. | May 2011 | A1 |
20110118660 | Torrance et al. | May 2011 | A1 |
20110130777 | Zhang et al. | Jun 2011 | A1 |
20110137140 | Tearney et al. | Jun 2011 | A1 |
20110144673 | Zhang et al. | Jun 2011 | A1 |
20110201924 | Tearney et al. | Aug 2011 | A1 |
20110208222 | Ljahnicky et al. | Aug 2011 | A1 |
20110257478 | Kleiner et al. | Oct 2011 | A1 |
20110264125 | Wilson et al. | Oct 2011 | A1 |
20110270187 | Nelson | Nov 2011 | A1 |
20110295148 | Destoumieux et al. | Dec 2011 | A1 |
20110301625 | Mauch et al. | Dec 2011 | A1 |
20110319905 | Palme et al. | Dec 2011 | A1 |
20120002928 | Irisawa | Jan 2012 | A1 |
20120004506 | Tearney et al. | Jan 2012 | A1 |
20120123352 | Fruland et al. | May 2012 | A1 |
20120136350 | Goshgarian et al. | May 2012 | A1 |
20120238869 | Schmitt et al. | Sep 2012 | A1 |
20120259337 | del Rio et al. | Oct 2012 | A1 |
20120277730 | Salahieh et al. | Nov 2012 | A1 |
20120289971 | Segermark et al. | Nov 2012 | A1 |
20130023865 | Steinke et al. | Jan 2013 | A1 |
20130035692 | Sorensen et al. | Feb 2013 | A1 |
20130072787 | Wallace et al. | Mar 2013 | A1 |
20130184549 | Avitall et al. | Jul 2013 | A1 |
20130211221 | Sunnarborg et al. | Aug 2013 | A1 |
20130223798 | Jenner et al. | Aug 2013 | A1 |
20130223801 | Bhagavatula et al. | Aug 2013 | A1 |
20130255069 | Higashi et al. | Oct 2013 | A1 |
20130266259 | Bhagavatula et al. | Oct 2013 | A1 |
20130287282 | Yokota et al. | Oct 2013 | A1 |
20130317519 | Romo et al. | Nov 2013 | A1 |
20130325003 | Kapur et al. | Dec 2013 | A1 |
20130331819 | Rosenman et al. | Dec 2013 | A1 |
20140005534 | He et al. | Jan 2014 | A1 |
20140046250 | Jain et al. | Feb 2014 | A1 |
20140128893 | Guggenheimer et al. | May 2014 | A1 |
20140187949 | Zhao et al. | Jul 2014 | A1 |
20140222042 | Kessler et al. | Aug 2014 | A1 |
20140222047 | Vreeman | Aug 2014 | A1 |
20140275996 | Stigall | Sep 2014 | A1 |
20140371718 | Alvarez et al. | Dec 2014 | A1 |
20150025310 | Everingham et al. | Jan 2015 | A1 |
20150141816 | Gupta et al. | May 2015 | A1 |
20150320975 | Simpson et al. | Nov 2015 | A1 |
20160008025 | Gupta et al. | Jan 2016 | A1 |
20160144155 | Simpson et al. | May 2016 | A1 |
20160262839 | Spencer et al. | Sep 2016 | A1 |
20170238808 | Simpson et al. | Aug 2017 | A1 |
20180042520 | Patel et al. | Feb 2018 | A1 |
20180207417 | Zung et al. | Jul 2018 | A1 |
20190021679 | Christensen | Jan 2019 | A1 |
20190029714 | Patel et al. | Jan 2019 | A1 |
20190110809 | Rosenthal et al. | Apr 2019 | A1 |
20190209206 | Patel et al. | Jul 2019 | A1 |
20190313941 | Radjabi | Oct 2019 | A1 |
20200029801 | Tachibana et al. | Jan 2020 | A1 |
20200060718 | Patel et al. | Feb 2020 | A1 |
20200069253 | Black et al. | Mar 2020 | A1 |
20200069327 | Patel et al. | Mar 2020 | A1 |
20200315654 | Patel et al. | Oct 2020 | A1 |
20200323553 | Fernandez et al. | Oct 2020 | A1 |
20210059713 | Patel et al. | Mar 2021 | A1 |
20210076949 | Smith et al. | Mar 2021 | A1 |
20211077262 | Spencer et al. | Jun 2021 | |
20210345903 | Patel et al. | Nov 2021 | A1 |
20220039828 | Patel et al. | Feb 2022 | A1 |
20220168011 | Patel et al. | Jun 2022 | A1 |
Number | Date | Country |
---|---|---|
1875242 | Dec 2006 | CN |
1947652 | Apr 2007 | CN |
101601581 | Dec 2009 | CN |
103027727 | Apr 2013 | CN |
104968285 | Oct 2015 | CN |
202006018883.5 | Feb 2007 | DE |
03470 | Dec 1989 | EP |
0808638 | Nov 1997 | EP |
0845692 | Nov 2005 | EP |
1859732 | Nov 2007 | EP |
2090245 | Aug 2009 | EP |
2353526 | Sep 2013 | EP |
S62-275425 | Nov 1987 | JP |
03502060 | Feb 1990 | JP |
H05501065 | Mar 1993 | JP |
05103763 | Apr 1993 | JP |
06027343 | Feb 1994 | JP |
H07184888 | Jul 1995 | JP |
07308393 | Nov 1995 | JP |
2002214127 | Jul 2002 | JP |
2004509695 | Apr 2004 | JP |
2004516073 | Jun 2004 | JP |
2005114473 | Apr 2005 | JP |
2005230550 | Sep 2005 | JP |
2005249704 | Sep 2005 | JP |
2005533533 | Nov 2005 | JP |
2008175698 | Jul 2006 | JP |
2006288775 | Oct 2006 | JP |
2006313158 | Nov 2006 | JP |
2006526790 | Nov 2006 | JP |
2006326157 | Dec 2006 | JP |
200783053 | Apr 2007 | JP |
200783057 | Apr 2007 | JP |
2007225349 | Sep 2007 | JP |
2007533361 | Nov 2007 | JP |
2008023627 | Feb 2008 | JP |
2008128708 | Jun 2008 | JP |
2008145376 | Jun 2008 | JP |
2008183208 | Aug 2008 | JP |
2008253492 | Oct 2008 | JP |
200914751 | Jan 2009 | JP |
2009509690 | Mar 2009 | JP |
200978150 | Apr 2009 | JP |
2009066252 | Apr 2009 | JP |
2009201969 | Sep 2009 | JP |
2010042182 | Feb 2010 | JP |
2010518900 | Jun 2010 | JP |
2011521747 | Jul 2011 | JP |
2012143558 | Aug 2012 | JP |
2012229976 | Nov 2012 | JP |
2012533353 | Dec 2012 | JP |
2013512736 | Apr 2013 | JP |
2013524930 | Jun 2013 | JP |
2015533584 | Nov 2015 | JP |
2016508758 | Mar 2016 | JP |
20070047221 | May 2007 | KR |
2185859 | Jul 2002 | RU |
221819102 | Dec 2003 | RU |
WO9117698 | Nov 1991 | WO |
WO9923958 | May 1999 | WO |
WO0054659 | Sep 2000 | WO |
WO0115609 | Mar 2001 | WO |
WO0176680 | Oct 2001 | WO |
WO2006133030 | Dec 2006 | WO |
WO2008005888 | Jan 2008 | WO |
WO2008029506 | Mar 2008 | WO |
WO2008042987 | Apr 2008 | WO |
WO2008051951 | May 2008 | WO |
WO2008065600 | Jun 2008 | WO |
WO2008086613 | Jul 2008 | WO |
WO2008087613 | Jul 2008 | WO |
WO2008151155 | Dec 2008 | WO |
WO2009005779 | Jan 2009 | WO |
WO2009006335 | Jan 2009 | WO |
WO2009009799 | Jan 2009 | WO |
WO2009009802 | Jan 2009 | WO |
WO2009023635 | Feb 2009 | WO |
WO2009024344 | Feb 2009 | WO |
WO2009094341 | Jul 2009 | WO |
WO2009140617 | Nov 2009 | WO |
WO2009148317 | Dec 2009 | WO |
WO2010039464 | Apr 2010 | WO |
WO2010056771 | May 2010 | WO |
WO2011044387 | Apr 2011 | WO |
WO2011062087 | May 2011 | WO |
WO2012057940 | May 2012 | WO |
WO2012061935 | May 2012 | WO |
WO2012123737 | Sep 2012 | WO |
WO2012166332 | Dec 2012 | WO |
WO2013033490 | Mar 2013 | WO |
WO2013056262 | Apr 2013 | WO |
WO2014077870 | May 2014 | WO |
WO2014093148 | Jun 2014 | WO |
Entry |
---|
Patel et al.; U.S. Appl. No. 17/347,419 entitled “Micro-molded anamorphic reflector lens for image guided therapeutic/diagnostic catheters,” filed Jun. 14, 2021. |
Gupta et al.; U.S. Appl. No. 17/445,648 entitled “Tissue collection device for catheter,” filed Aug. 23, 2021. |
Simpson et al.; U.S. Appl. No. 17/449,867 entitled “Occlusion-crossing devices, imaging, and atherectomy devices,” filed Oct. 4, 2021. |
Spencer et al.; U.S. Appl. No. 17/449,895 entitled “Occlusion-crossing devices, atherectomy devices, and imaging,” filed Oct. 4, 2021. |
Tachibana et al.; U.S. Appl. No. 17/645,722 entitled “Atherectomy catheter drive assemblies,” filed Dec. 22, 2021. |
Black et al.; U.S. Appl. No. 17/652,073 entitled “Optical coherence tomography for biological imaging,” filed Feb. 22, 2022. |
Patel et al.; U.S. Appl. No. 17/762,815 entitled “Atherectomy catheter with shapeable distal tip,” filed Mar. 23, 2022. |
Patel et al.; U.S. Appl. No. 17/763,810 entitled “Occlusion-crossing devices,” filed Mar. 25, 2022. |
Patel et al.; U.S. Appl. No. 17/455,655 entitled “Atherectomy catheter with shapeable distal tip,” filed Nov. 18, 2021. |
Aziz et al.; Chronic total occlusions—a stiff challege requiring a major breakthrough: is there light at the end of the tunnel?; Heart; vol. 91; suppl. III; pp. 42-48; Jun. 2005. |
Bayer Material Science: ; Snap-Fit Joints for Plastics; 26 pages; retrieved from the Internet: ( https://web.archive.org/web/20121119232733if_/http://fab.cba.mit.edu:80/classes/S62.12/people/vemelle.noel/Plastic_ Snap_fit_design.pdf) on Sep. 26, 2018. |
Choma et al.; Sensitivity advantage of swept source and fourier domain optical coherence tomography; Optics Express: 11(18); pp. 2183-2189; Sep. 8, 2003. |
De Boer et al.; Improved signal-to-noise ratio in spectral-domain compared with time-domain optical coherence tomography; Optics Letters; 28(21); pp. 2067-2069; Nov. 2003. |
Emkey et al.; Analysis and evaluation of graded-index fiber-lenses: Journal of Lightwave Technology; vol. LT-5: No. 9; pp. 1156-1164; Sep. 1987. |
Gonzalo et al.; Optical coherence tomography patterns of stent restenosis; Am. Heart J.; 158(2); pp. 284-293; Aug. 2009. |
Han et al.; In situ Frog Retina Imaging Using Common-Path OCT with a Gold-Coated Bare Fiber Probe; CFM6; San Jose, California; CLEO, May 4, 2008; 2 pages. |
Leitgeb et al.; Performance of fourier domain vs time domain optical coherence tomography; Optics Express; 11(8); pp. 889-894; Apr. 21, 2003. |
Linares et al.; Arbitrary single-mode coupling by tapered and nontapered grin fiber lenses; Applied Optics; vol. 29; No. 28; pp. 4003-4007; Oct. 1, 1990. |
Merriam Webster; Proximal (Definition); 10 pages; retrieved from the internet (https://www.merriam-webster.com/dictionary/proximal) on Jun. 9, 2021. |
Muller et al.; Time-gated infrared fourier-domain optical coherence tomography; CFM5; San Jose, California; CLEO May 4, 2008; 2 pages. |
Rollins et al.; Optimal interferometer designs for optical coherence tomography; Optics Letters; 24(21); pp. 1484-1486; Nov. 1999. |
Schmitt et al.; A new rotational thrombectomy catheter: System design and first clinical experiences; Cardiovascular and Interventional Radiology; Springer-Verlag; 22(6); pp. 504-509; Nov. 1, 1999. |
Sharma et al.; Common-path optical coherence tomography with side-viewing bare fiber probe for endoscopic optical coherence tomography; Rev. Sci. Instrum.; vol. 78; 113102; 5 pages: Nov. 6, 2007. |
Sharma et al.; Optical coherence tomography based on an all-fiber autocorrelator using probe-end reflection as reference; CWJ13; San Francisco, California; CLEO May 16, 2004; 4 pages. |
Shinkle et al.; Evaluation of stent placement and outcomes with optical coherence tomography; Interv. Cardiol.; 2(4); pp. 535-543; (manuscript version, 12 pages); Aug. 2010. |
Stamper et al.; Plaque characterization with optical coherence tomography. Journal of the American College of Cardiology. 47(8); pp. 69-79; Apr. 18, 2006. |
Suparno et al.; Light scattering with single-mode fiber collimators; Applied Optics; vol. 33; No. 30; pp. 7200-7205; Oct. 20, 1994. |
Tanaka et al.; Challenges on the frontier of intracoronary imaging: atherosclerotic plaque macrophage measurement by optical coherence tomography; Journal of Biomedical Optics; 15(1); pp. (011104-1)-(011104-8); Jan.-Feb. 2010. |
Wang et al.; Common-path endoscopic Fourier domain OCT with a reference Michelson interferometer; Proceedings of the SPIE; vol. 7566; pp. 75660L-75660L-7; Jan. 2010. |
Wikipedia; Hinge; 4 pages; retrieved from the internet (https://en.wikipedia.org/w/index.php?title=Hinge&oldid:=479569345) on Jun. 9, 2021. |
Simpson et al.; U.S. Appl. No. 17/075,548 entitled “Identification of elastic lamina to guide interventional therapy,” filed Oct. 20, 2020. |
Smith et al.; U.S. Appl. No. 17/189,123 entitled “Optical pressure sensor assembly,” filed Mar. 1, 2021. |
Newhauser et al.; U.S. Appl. No. 17/209,168 entitled “Occlusion-crossing devices,” filed Mar. 22, 2021. |
Number | Date | Country | |
---|---|---|---|
20220007941 A1 | Jan 2022 | US |
Number | Date | Country | |
---|---|---|---|
61646783 | May 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15419815 | Jan 2017 | US |
Child | 17209162 | US | |
Parent | 14400140 | US | |
Child | 15419815 | US |